September 1998 in “Journal of The European Academy of Dermatology and Venereology” Phototrichogram helps assess hair loss severity.
September 1998 in “Journal of The European Academy of Dermatology and Venereology” Auto-portraits help evaluate scalp hair.
421 citations,
April 2012 in “The New England Journal of Medicine” Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.
290 citations,
December 2017 in “Journal of The American Academy of Dermatology” Alopecia areata is an autoimmune condition causing hair loss, influenced by genetics, stress, and diet, and may be prevented by a high soy oil diet.
205 citations,
April 2013 in “British Journal of Dermatology” Platelet-rich plasma treatment significantly increased hair regrowth and decreased discomfort in alopecia patients, making it a potentially better and safer treatment option.
191 citations,
May 2018 in “British journal of dermatology/British journal of dermatology, Supplement” Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.
148 citations,
December 2018 in “Journal of autoimmunity” Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.
106 citations,
June 2005 in “Journal of Investigative Dermatology” The document concludes that assessing hair follicle damage due to cyclophosphamide in mice involves analyzing structural changes and suggests a scoring system for standardized evaluation.
85 citations,
October 2012 in “Dermatologic Clinics” Alopecia Areata is an autoimmune condition often starting before age 20, with varied treatment success and a need for personalized treatment plans.
80 citations,
October 1983 in “BMJ” Minoxidil helps hair regrowth in alopecia patients, with 16 having good results and no side effects.
64 citations,
July 2016 in “Journal of Immunology” Blocking the CXCR3 receptor reduces T cell accumulation in the skin and prevents hair loss in mice.
64 citations,
November 2008 in “Journal of The American Academy of Dermatology” A new type of rapid hair loss called ADTA usually gets better on its own within 6 months.
60 citations,
September 2015 in “Expert Review of Clinical Immunology” Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.
59 citations,
October 2012 in “Pharmaceutical Research” Squalene-based carriers improve delivery of a treatment to hair follicles for alopecia areata.
55 citations,
October 2019 in “Dermatology and therapy” Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
49 citations,
January 2003 in “American Journal of Clinical Dermatology” Effective management of children's hair loss involves accurate diagnosis, various treatments, and supportive care.
44 citations,
February 2015 in “Journal of the American Academy of Dermatology” Combining diphenylcyclopropenone with anthralin is more effective for hair regrowth in alopecia areata than using diphenylcyclopropenone alone, but may cause more side effects.
41 citations,
February 2001 in “Current pharmaceutical design” Current and future treatments for alopecia areata focus on immunosuppression, immunomodulation, and protecting hair follicles.
40 citations,
August 2022 in “Frontiers in immunology” Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.
36 citations,
April 2016 in “British journal of dermatology/British journal of dermatology, Supplement” A substance called VIP might protect hair follicles from being attacked by the immune system, and problems with VIP signaling could lead to hair loss in alopecia areata.
27 citations,
September 2014 in “JAMA dermatology” Female donor to male recipient sex mismatch and positive ACA-IgG are key risk factors for vitiligo and alopecia areata in chronic GvHD patients.
23 citations,
October 2018 in “Expert Opinion on Drug Safety” Consider benefits and risks of new alopecia treatments for safety.
20 citations,
December 2019 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.
20 citations,
January 2013 in “Evidence-based complementary and alternative medicine” TGPC plus CGT is effective and safe for treating severe alopecia areata in children.
19 citations,
October 2017 in “European Journal of Pharmaceutics and Biopharmaceutics” The gel made of minoxidil and hydroxypropyl-β-cyclodextrin improves hair growth and is good for long-term use.
18 citations,
April 2013 in “PLOS ONE” Mice with autoimmune hair loss showed signs of heart problems.
17 citations,
June 2017 in “British Journal of Dermatology” The article concludes that hair loss is a common side effect of drugs treating skin cancer by blocking the hedgehog pathway, but treatment should continue, and more selective drugs might prevent this side effect.
17 citations,
September 2003 in “Journal of Investigative Dermatology Symposium Proceedings” Old treatments for other skin conditions showed promise for hair regrowth in mice with a hair loss condition.
16 citations,
November 2016 in “Journal of Cosmetic and Laser Therapy” Laser and light therapies, especially the 308 nm excimer laser, are effective and safe for treating alopecia areata, but more research is needed.
16 citations,
January 2015 in “Current problems in dermatology” Alopecia Areata is an autoimmune hair loss condition that needs more research for better treatments.